The mission of the NanoBiotechnology Center at Roswell Park Cancer Institute (NBC@RPCI) is to carry out multidisciplinary research on important cancer related problems, primarily the imaging, detection, and treatment of cancer.

We identify a specific clinical problem, then design, synthesize, characterize and use nanodevices to solve that very issue by biophysical approaches utilizing the latest achievements of nanotechnology and cancer research.

Presently we focus on a composite nanodevice platform, where targeted or non-targeted nanodevices utilize radiation and/or electromagnetic fields. Active and passive biophysical properties are being exploited to provide improved imaging and therapy.

A molecular targeted approach, i.e., targeting specific receptors in or on tumor cells or the angiogenic microvasculature surrounding the tumor is also actively researched. These next generation nanodevices will significantly advance the in vivo and ex vivo detection, diagnosis, and treatment of cancer.

We have already conceptualized and described: dendrimer template and nanocomposite synthesis, characterization, toxicity, and biodistribution of non-targeted and targeted multifunctional nanodevices, selective targeting of specific organs, selective targeting of integrins, and nano-brachytherapy. Further research results are being added. For details, see our list of publications.

As Upstate New York’s only NCI-designated comprehensive Cancer Center, Roswell Park has a long tradition of collaboration within scientists’ of various disciplines locally, regionally, nationally and internationally. The NBC at RPCI combines the expertise of scientists and practitioners of different backgrounds to translate nanobiotechnology through materials and translational research into clinical practice.